Inozyme Pharma develops treatments for rare genetic diseases involving abnormal mineralization. Their key product candidate, INZ-701, is a protein for treating ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. The company has a license agreement with Yale University and is based in Boston, Massachusetts.